Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee.
Authors
Califano, RaffaeleKaramouzis, M
Banerjee, S
de Azambuja, E
Guarneri, V
Hutka, M
Jordan, K
Kamposioras, K
Martinelli, E
Corral, J
Postel-Vinay, S
Preusser, M
Porcu, L
Torri, V
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Medical Oncology, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom.Issue Date
2014-03-16
Metadata
Show full item recordAbstract
Early stage Non-Small Cell Lung Cancer (NSCLC) is potentially curable with surgery. ESMO guidelines recommend cisplatin-based adjuvant chemotherapy (CT) for completely resected stage II-III NSCLC. There is limited evidence for the use of adjuvant CT and/or radiotherapy (RT) in incompletely resected (R1) early stage NSCLC.Citation
Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee. 2014: Lung CancerJournal
Lung CancerDOI
10.1016/j.lungcan.2014.03.010PubMed ID
24746176Type
ArticleLanguage
enISSN
1872-8332ae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2014.03.010